Premium
Abatacept: first T cell co‐stimulation modulator for severe active RA
Author(s) -
Chaplin Steve,
Ostor Andrew
Publication year - 2007
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.161
Subject(s) - abatacept , medicine , methotrexate , adverse effect , co stimulation , pharmacology , immunology , t cell , immune system , rituximab , lymphoma , cd28
Abatacept (Orencia) is licensed for the treatment of severe RA in combination with methotrexate when at least one anti‐TNF agent has failed. Here, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Andrew Ostor comments on its place in RA therapy. Copyright © 2007 Wiley Interface Ltd